Biomarkers and risk factors for the early prediction of immune-related adverse events: a review

References

• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–12. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J clin oncol. 2017;35(34):3815–22. doi:10.1200/JCO.2016.72.1167.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. doi:10.1016/j.ctrv.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55. doi:10.1056/NEJMoa1609214.
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1043–47. doi:10.1001/jamaoncol.2019.0402.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–08. doi:10.1126/science.aao3290.
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79. doi:10.1093/annonc/mdx108.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. doi:10.1126/scitranslmed.3008002.
   PubMed Web of Science ®Google Scholar
• Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, Jiang -L-L, Sun H, Qin T-J, Guo H, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284. doi:10.1186/s13046-020-01749-x.
   PubMed Web of Science ®Google Scholar
• El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. doi:10.1016/j.critrevonc.2017.09.002.
   PubMed Web of Science ®Google Scholar
• Kottschade LA. Incidence and management of immune-related adverse events in patients undergoing treatment with immune checkpoint inhibitors. Curr Oncol Rep. 2018;20(3):24. doi:10.1007/s11912-018-0671-4.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–28. doi:10.1001/jamaoncol.2018.3923.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017;69:687–99. doi:10.1002/art.40043.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82. doi:10.1001/jamaoncol.2017.3064.
   PubMed Web of Science ®Google Scholar
• Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2018;19(3):e335–e48. doi:10.1016/j.cllc.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315–29. doi:10.1002/hep.31227.
   PubMed Web of Science ®Google Scholar
• Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv264–iv6. doi:10.1093/annonc/mdy162.
   PubMed Web of Science ®Google Scholar
• Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019;34(1):108–17. doi:10.1093/ndt/gfy105.
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi:10.1016/j.jacc.2018.02.037.
   PubMed Web of Science ®Google Scholar
• Hsu C, Marshall JL, He AR. Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment. The Oncologist. 2020;25(2):105–11. doi:10.1634/theoncologist.2018-0162.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14. doi:10.1016/j.ejca.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Bomze D, Ring SS, Berner F, Fässler M, Diem S, Abdou M-T, Hammers C, Emtenani S, Braun A, et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol. 2020;82(4):854–61. doi:10.1016/j.jaad.2019.08.045.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Gosho M, Tanaka R, Yamaguchi K, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 2017;88(2):225–31. doi:10.1016/j.jdermsci.2017.07.007.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji -R-R. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11(1):75. doi:10.1186/1479-5876-11-75.
   PubMedGoogle Scholar
• Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, et al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer. 2021;12(2):153–64. doi:10.1111/1759-7714.13736.
   PubMed Web of Science ®Google Scholar
• Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020;111(5):1468–77. doi:10.1111/cas.14363.
   PubMed Web of Science ®Google Scholar
• Yano S, Ashida K, Sakamoto R, Sakaguchi C, Ogata M, Maruyama K, Sakamoto S, Ikeda M, Ohe K, Akasu S, et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198–203. doi:10.1016/j.ejca.2020.02.049.
   PubMed Web of Science ®Google Scholar
• Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80. doi:10.2337/dbi18-0002.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology. 2019;58(3):476–80. doi:10.1093/rheumatology/key358.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J clin oncol. 2018;36(17):1714–68. doi:10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Makino T, Ishii N, Hashimoto T, Shimizu T. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid. Eur J Dermatol. 2019;29(5):554–55. doi:10.1684/ejd.2019.3618.
   PubMed Web of Science ®Google Scholar
• Master SR, Robinson A, Mills GM, Mansour RP. Cardiovascular complications of immune checkpoint inhibitor therapy. J Clin Oncol. 2019;37(15_suppl):2568. doi:10.1200/JCO.2019.37.15_suppl.2568.
   Google Scholar
• Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J-P, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89. doi:10.1016/S1470-2045(18)30608-9.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477–83. doi:10.1038/nm955.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J clin oncol. 2017;35(7):709–17. doi:10.1200/JCO.2016.68.2005.
   PubMed Web of Science ®Google Scholar
• Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, et al. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. Cancer Immunol Immunother. 2018;67(8):1197–208. doi:10.1007/s00262-018-2178-0.
   PubMed Web of Science ®Google Scholar
• Iwama S, Kobayashi T, Arima H. Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors. Endocrinol Metab. 2021;36(2):312–21. doi:10.3803/EnM.2021.1007.
   Google Scholar
• Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol. 2021. doi:10.1002/art.41949.
   Web of Science ®Google Scholar
• Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz H-M, Hassel JC. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67(2):175–82. doi:10.1007/s00262-017-2069-9.
   PubMed Web of Science ®Google Scholar
• Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis. 2019;22(2):297–302. doi:10.1111/1756-185X.13444.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jaquith JM, McCarthy-Fruin K, Zhu X, Zhou X, Li Y, Crowson C, Davis JM, Thanarajasingam U, Zeng H, et al. Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. 2020;39(12):3631–37. doi:10.1007/s10067-020-05162-9.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569–79. doi:10.1038/s41584-018-0074-9.
   PubMed Web of Science ®Google Scholar
• Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634. doi:10.3389/fneur.2020.00634.
   PubMed Web of Science ®Google Scholar
• Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020;19(4):479–88. doi:10.1080/14740338.2020.1738382.
   PubMed Web of Science ®Google Scholar
• Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M, Saito H, Suzuki N, Brunner-Weinzierl M, Bauer J, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139(11):2923–34. doi:10.1093/brain/aww225.
   PubMedGoogle Scholar
• Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. The Oncologist. 2019;24(8):1128–36. doi:10.1634/theoncologist.2018-0563.
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, Hogg D, Butler MO, Joshua AM. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792–99. doi:10.1002/cam4.878.
   PubMed Web of Science ®Google Scholar
• Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol. 2019;145(10):2625–31. doi:10.1007/s00432-019-03002-1.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget. 2018;9(21):15542–51. doi:10.18632/oncotarget.24509.
   PubMedGoogle Scholar
• Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715–20. doi:10.1172/JCI96798.
   PubMed Web of Science ®Google Scholar
• Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsusita A, Kawasumi H, Nasu S, Tanaka A, Morishita N, Kawahara K, et al. Significance of pre-treatment interferon-gamma release in patients with non-small-cell lung cancer receiving immune checkpoint inhibitors. Anticancer Res. 2020;40(12):6971–78. doi:10.21873/anticanres.14721.
   PubMed Web of Science ®Google Scholar
• Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-mccutchen Y, Lu R, Xie Y, Li Q, Wakeland E, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63–68. doi:10.1038/s41416-018-0155-1.
   Web of Science ®Google Scholar
• Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11(1):4946. doi:10.1038/s41467-020-18742-9.
   PubMed Web of Science ®Google Scholar
• Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, et al. Relationship between programmed cell death protein ligand 1 expression and immune-related adverse events in non-small-cell lung cancer patients treated with pembrolizumab. Jma J. 2020;3(1):58–66. doi:10.31662/jmaj.2019-0005.
   PubMedGoogle Scholar
• Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47(7–8):1650–60. doi:10.1016/j.molimm.2010.02.008.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kakizaki A, Furudate S, Aiba S. A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid. Exp Dermatol. 2017;26(12):1193–98. doi:10.1111/exd.13157.
   PubMed Web of Science ®Google Scholar
• Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL. CD4 T cell-derived IFN-γ plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016;12(5):e1005667. doi:10.1371/journal.ppat.1005667.
   PubMed Web of Science ®Google Scholar
• Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E. Predictors of the onset of type 1 diabetes obtained from real-world data analysis in cancer patients treated with immune checkpoint inhibitors. Asian Pac J Cancer Prev. 2020;21:1697–99. doi:10.31557/APJCP.2020.21.6.1697.
   PubMedGoogle Scholar
• Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, et al. Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal? Oncologist. 2019;24(11):e1148–e55. doi:10.1634/theoncologist.2019-0094.
   PubMed Web of Science ®Google Scholar
• Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018;25(5):e403–e10. doi:10.3747/co.25.4047.
   PubMed Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr., Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–95. doi:10.1016/j.lungcan.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Marur S, Singh H, Mishra-Kalyani P, Larkins E, Keegan P, Sridhara R, Blumenthal GM, Pazdur R. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Semin Oncol. 2018;45:220–25. doi:10.1053/j.seminoncol.2018.08.007.
   PubMed Web of Science ®Google Scholar
• Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep. 2020;10(1):13773. doi:10.1038/s41598-020-70743-2.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig. 2019;57(5):451–59. doi:10.1016/j.resinv.2019.05.002.
   Web of Science ®Google Scholar
• Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847–55 doi:10.1111/1759-7714.12759.
   Web of Science ®Google Scholar
• Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F, Han C, Long Y, Li Y, Zheng X, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med. 2018;7(8):4115–20. doi:10.1002/cam4.1579.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer. 2020;128:17–26. doi:10.1016/j.ejca.2019.12.031.
   PubMed Web of Science ®Google Scholar
• Wang S, Cowley LA, Liu XS. Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules. 2019;24(18):3214. doi:10.3390/molecules24183214.
   Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J clin oncol. 2017;35(7):785–92. doi:10.1200/JCO.2015.66.1389.
   PubMed Web of Science ®Google Scholar
• Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209. doi:10.1016/j.ejca.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, et al. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer. 2020;11(4):1052–60. doi:10.1111/1759-7714.13364.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J clin oncol. 2016;34(34):4102–09. doi:10.1200/JCO.2016.67.2477.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608 doi:10.1158/1535-7163.MCT-17-0386.
   Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Adam T, Becker TM, Chua W, Bray V, Roberts TL. The multiple potential biomarkers for predicting immunotherapy response-finding the needle in the haystack. Cancers (Basel). 2021;13(2):277. doi:10.3390/cancers13020277.
   Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. (18)F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol. 2018;46:260–64. doi:10.2967/jnmt.117.204933.
   PubMed Web of Science ®Google Scholar
• Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018;36(4):601–07. doi:10.1007/s10637-017-0524-2.
   Web of Science ®Google Scholar
• June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles‘ heel of cancer immunotherapy? Nat Med. 2017;23(5):540–47. doi:10.1038/nm.4321.
   PubMed Web of Science ®Google Scholar
• Von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem. 2020;66(6):779–93. doi:10.1093/clinchem/hvaa081.
   PubMed Web of Science ®Google Scholar
• Akinci Ozyurek B, Sahin Ozdemirel T, Buyukyaylaci Ozden S, Erdogan Y, Kaplan B, Kaplan T. Prognostic value of the Neutrophil to Lymphocyte Ratio (NLR) in lung cancer cases. Asian Pac J Cancer Prev. 2017;18(5):1417–21. doi:10.22034/APJCP.2017.18.5.1417.
   PubMedGoogle Scholar
• Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, Satsutani N, Ogata M, Miyara T, Nomura S, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 2018;23(4):634–40. doi:10.1007/s10147-018-1250-2.
   PubMed Web of Science ®Google Scholar
• Gu X, Sun S, Gao XS, Xiong W, Qin S, Qi X, Ma M, Li X, Zhou D, Wang W, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6(1):23893. doi:10.1038/srep23893.
   PubMedGoogle Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. doi:10.1016/S0140-6736(18)32409-7.
   PubMed Web of Science ®Google Scholar
• Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579(7800):507–17. doi:10.1038/s41586-020-2124-0.
   PubMed Web of Science ®Google Scholar
• Fillon M. Exercise and nutrition may prolong the lives of patients with colon cancer. CA Cancer J Clin. 2018;68(5):319–21. doi:10.3322/caac.21430.
   PubMed Web of Science ®Google Scholar